Zoekresultaten - 6 results
Prevalence Estimation Of HCV Among People Who Inject Drugs In Belgium Through Respondent Driven Sampling, Capture-Recapture And Multiplier Method
the same time period we also obtained pseudo-anonymized identifier information from treatment and harm reduction service providers. We estimated the total number of PWID in Brussels using ...
Challenges to Differentiate Hepatitis C Genotype 1 and 6: Results from A Field-Study in Cambodia.
classification (1 or 6) remained inconclusive in 15% of samples. The locally available method (LightPower assay) failed to identify genotype 6 non-a/non-b, which highlights that methods using 5’ UTR information ...
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.
envelope protein 1 (E1) are not fully identified. Here we describe the detailed characterization of a human mAb, designated A6, generated from an HCV genotype 1b infected patient. ELISA results showed ...
Diagnostic hepatitis C testing of people in treatment for substance use disorders in Belgium between 2011 and 2014: a cross-sectional study.
recently injected were tested for HCV RNA. CONCLUSIONS: This study supports the need of a continued effort of health care providers to identify people infected with HCV. For a population at risk such as ...
Estimates of people who injected drugs within the last 12 months in Belgium based on a capture-recapture and multiplier method
obtained pseudo-anonymized identifier information from treatment and harm reduction service providers and a fieldwork study between February and April 2019 in Brussels. We estimated the number of PWID, ...
Stable HEV IgG seroprevalence in Belgium between 2006 and 2014.
sexes were found. Modelling identified the individual’s age and province as relevant factors. The probability of HEV seropositivity increases significantly with age. An estimated total of 434 819 (yearly ...